- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03811405
Physiology, Imaging and Modeling of Essential Tremor
Physiology, Imaging and Modeling of Deep Brain Stimulation for Essential Tremor
Study Overview
Status
Conditions
Detailed Description
Deep brain stimulation (DBS) is a neuromodulatory therapy that is effective in a subset of well selected essential tremor (ET) patients. However, as many as 1/5 of patients may initially improve, but then steadily worsen following the operation. The investigators developed a technique to study a variety of alternative stimulation methods without the use of an invasive repeat surgical intervention.
The electrophysiological effects of non-conventional DBS differ from traditional DBS, however the physiological differences in the setting of human tremor remain largely unknown. This study plans to explore gaps in knowledge of neuromodulation and will collect and contribute essential information to the underlying mechanism of action of DBS. The hypothesis of this project centers around active biphasic stimulation providing a wider therapeutic window and a lower adverse event profile as compared to conventional DBS.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Leonardo B Almeida, MD
- Phone Number: (352) 294-5400
- Email: Leonardo.BritodeAlmeida@neurology.ufl.edu
Study Contact Backup
- Name: Joshua K Wong, MD
- Phone Number: (352) 294-5400
- Email: joshua.wong@neurology.ufl.edu
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Recruiting
- UF Health at the University of Florida
-
Gainesville, Florida, United States, 32611
- Not yet recruiting
- McKnight Brain Institute--Fixel Center for Neurological Diseases
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Existing unilateral or bilateral VIN DBS for ET, non-demented (MMSE>24), and must have a documented suboptimal tremor suppression on two successive visits (compared to the baseline post-operative improvement at 6 months following ET DBS surgery). For bilateral cases, the most affected tremor side will be studied.
Exclusion Criteria:
- No diagnosis of Essential Tremor
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with Essential Tremor
Patients with chronically implanted DBS devices for ET who experience progressive worsening of tremor symptoms over time.
The DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
The following random conditions will be applied: (1) Home Settings; (2) VIN Biphasic; (3) Stimulator Off.
A 30-minute washout period will be applied between each of the random conditions.
Therefore, each patient will serve as their own control.
|
During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Volume of tissue activated from stimulation with ET DBS
Time Frame: up to 24 hours
|
The study team will use computer simulation and virtual reconstruction of the brain from pre-operative MRI data to calculate the volume of tissue activated (VTA) from the novel stimulation patterns.
The investigators will assess the feasibility of the patterns to address the worsening of ET that may occur in 20% or more of the ET population.
|
up to 24 hours
|
Baseline DBS settings versus active biphasic pulse DBS settings
Time Frame: up to 1 hour
|
The investigators will compare the degree of tremor suppression from the most optimal DBS settings that can be obtained via traditional programming methods versus active biphasic DBS.
The degree of tremor will be quantified by multiple clinical metrics including the Fahn-Tolosa-Marin Tremor Rating Scale and Kinesia ONE® accelerometer system.
|
up to 1 hour
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Fahn-Tolosa-Marin Tremor Rating Scale
Time Frame: up to 15 minutes
|
Essential tremor severity will be assessed by the clinically validated Fahn-Tolosa-Marin Tremor Rating Scale (FTMTRS).
It is a 0 to 4 scale (0 = no tremor; 4 = severe amplitude of tremor) of 9 different parts of the body.
The FTMTRS will be assessed for the various DBS settings.
|
up to 15 minutes
|
Tremor motor physiology
Time Frame: up to 15 minutes
|
Essential tremor motor physiology will be recorded by the Kinesia ONE accelerometer system.
THe Kinesia ONE system is a wireless wearable motion sensor unit and portable transducer that translates the degree of movement into a standardized scale.
Tremor physiology will be assessed for the various DBS settings.
|
up to 15 minutes
|
Gait impairment
Time Frame: up to 15 minutes
|
Essential tremor's effect on gait will be assessed by the GAITRite system.
Patients will walk along a GAITRite floor mat to have the various gait parameters such as step time, cycle time, step length, stride length, etc measured.
Gait parameters will be assessed on the various DBS settings.
|
up to 15 minutes
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Leonardo B Almeida, MD, Univeristy of Florida
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB201802397 -N -A
- OCR19607 (Other Identifier: UF OnCore)
- MEDTRONIC INC (Other Identifier: AGR00011004)
- 5R25NS108939-04 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Active biphasic pulse stimulation---Home Settings
-
Cognito Therapeutics, Inc.Active, not recruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Dementia, Alzheimer Type | Dementia Alzheimers | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Dementia, MildUnited States
-
Massachusetts Institute of TechnologyActive, not recruitingAlzheimer Disease | Alzheimer DementiaUnited States
-
Massachusetts Institute of TechnologyActive, not recruitingAlzheimer DiseaseUnited States
-
Massachusetts Institute of TechnologyRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Alzheimer'sUnited States
-
Massachusetts Institute of TechnologyRecruiting
-
Changping LaboratoryRecruiting
-
Massachusetts Institute of TechnologyRecruitingParkinson DiseaseUnited States
-
Western University, CanadaRecruiting
-
University of FloridaRecruiting
-
Hospital de Clinicas de Porto AlegreCompletedHealthy Participants | Transcranial Direct Current StimulationBrazil